Ouro Medicines, a San Francisco, CA-based biotechnology firm creating immune reset therapeutics for folks residing with power immune-mediated ailments, launched with $120m in Sequence A funding.
The Sequence A was co-led by TPG Life Sciences Improvements, NEA, and Norwest Enterprise Companions, with participation from Monograph Capital, GSK, UPMC Enterprises, Boyu/Zoo Capital, LongRiver Investments, and different unnamed traders.
Based by Monograph Capital in partnership with GSK plc., Ouro Medicines is a biotechnology firm devoted to creating immune reset therapeutics for folks residing with power immune-mediated ailments. Its most superior product candidate is OM336, a BCMA-directed, bispecific T cell engager not too long ago licensed from Keymed Biosciences (2162.HK). BCMA is extremely expressed throughout a number of B cell subtypes that play a job in driving a number of indications the place excessive specificity and efficiency are wanted to realize near-complete B cell depletion.
Keymed Biosciences is at the moment finding out OM336 (CM336) in an ongoing Part 2 growth research in a number of myeloma in China. Ouro holds unique rights exterior of Larger China and intends to begin its first Part 1 research in 2025. Examples of B cell mediated ailments embrace systemic lupus erythematosus, scleroderma, rheumatoid arthritis, Sjögren’s, and myositis. Supportive proof of idea information has been generated from the off-label use of BCMA-directed TCEs in these indications.
Behind its lead program, the corporate intends to advance a broad set of discovery applications concentrating on extra dimensions of B cell biology. These applications probe distinctive subsets of B cells in comparison with present therapies within the clinic. Moreover, the corporate’s protein engineering experience is being utilized to next-generation variations of novel TCEs to proceed to drive modern remedies for power immune-mediated ailments.
Ouro has assembled a management group with experience in a variety of related ailments and modalities, together with:
- Jaideep Dudani, PhD, Chief Government Officer.
- Neely Mozaffarian, MD, PhD, Chief Medical Officer.
- Christina Carlson, JD, Chief Administrative Officer.
- Kevin P. Baker, PhD, Chief Growth Officer.
Ouro’s Board of Administrators contains Shinichiro Fuse, PhD (TPG), Matt McAviney, MD (NEA), Brian Matesic, MD (Norwest), Tim Funnell, DPhil (Monograph), and Bo Chen, PhD (Keymed).
Supporting the Ouro management group are a number of deeply skilled scientific advisors, together with John Davis, MD, MPH, President, Norte Well being Consulting and former scientific advisory board member of HI-Bio; Matthew Baker, MD, MS, Scientific Chief within the Division of Immunology and Rheumatology at Stanford College and the Co-Director of the Stanford Multidisciplinary Sarcoidosis Program; and Stanford Peng, MD, PhD, most not too long ago President and Head of Analysis & Growth at Alpine Immune Sciences.
FinSMEs
10/01/2025
